Maze Therapeutics Ownership | Who Owns Maze Therapeutics?
Maze Therapeutics Ownership Summary
Maze Therapeutics is owned by 25.04% institutional investors, 1.46% insiders, and 73.50% retail investors. Frazier life sciences management is the largest institutional shareholder, holding 10.63% of MAZE shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.34% of its assets in Maze Therapeutics shares.
MAZE Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Maze Therapeutics | 25.04% | 1.46% | 73.50% |
| Sector | Healthcare Stocks | 35.70% | 12.04% | 52.26% |
| Industry | Biotech Stocks | 35.48% | 11.92% | 52.60% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Frazier life sciences management | 4.57M | 10.63% | $136.33M |
| Trv gp iv | 4.47M | 10.41% | $133.55M |
| Arch venture management | 4.12M | 9.59% | $122.98M |
| Deep track capital, lp | 3.48M | 8.09% | $103.81M |
| Janus henderson group | 2.86M | 6.65% | $85.28M |
| Paradigm biocapital advisors lp | 2.74M | 6.39% | $81.92M |
| Blackrock funding, inc. /de | 2.57M | 5.98% | $76.73M |
| Ah capital management | 1.70M | 3.96% | $50.81M |
| Vr adviser | 1.60M | 3.73% | $47.82M |
| Vanguard group | 1.70M | 3.71% | $70.31M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Trv gp iv | 4.47M | 50.04% | $133.55M |
| Arch venture management | 4.12M | 18.16% | $122.98M |
| General catalyst group management | 1.04M | 16.85% | $30.92M |
| Trv gp v | 950.80K | 7.08% | $28.38M |
| Ah capital management | 1.70M | 3.94% | $50.81M |
| Frazier life sciences management | 4.57M | 3.51% | $136.33M |
| Foresite capital management iv | 156.90K | 1.98% | $4.68M |
| Logos global management lp | 1.24M | 1.84% | $36.86M |
| Vr adviser | 1.60M | 1.78% | $47.82M |
| Casdin capital | 758.86K | 1.72% | $22.65M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Paradigm biocapital advisors lp | 2.74M | 1.67% | 2.74M |
| Adage capital partners gp | 1.18M | 0.05% | 1.18M |
| Cormorant asset management, lp | 750.00K | 1.12% | 750.00K |
| Farallon capital management | 373.00K | 0.06% | 373.00K |
| Vanguard group | 1.70M | 0.00% | 362.06K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Bellevue group | - | - | -887.71K |
| Deep track capital, lp | 3.48M | 1.70% | -768.88K |
| Marshall wace, llp | 310.64K | 0.01% | -536.83K |
| Matrix capital management company, lp | - | - | -480.00K |
| Woodline partners lp | 650.23K | 0.07% | -385.00K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Paradigm biocapital advisors lp | 2.74M | 1.67% | 2.74M | $81.92M |
| Adage capital partners gp | 1.18M | 0.05% | 1.18M | $35.16M |
| Cormorant asset management, lp | 750.00K | 1.12% | 750.00K | $22.39M |
| Farallon capital management | 373.00K | 0.06% | 373.00K | $11.13M |
| Candriam s.c.a. | 278.17K | 0.04% | 278.17K | $8.30M |
Sold Out
| Holder | Change |
|---|---|
| True wealth design | -5.00 |
| Daiwa securities group | -160.00 |
| Srs capital advisors | -307.00 |
| Comerica bank | -636.00 |
| Amalgamated bank | -674.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | 57 | -60.42% | 10,759,374 | -77.75% | 25 | 0.22% | 36 | -65.71% | 9 | -55.00% |
| Dec 31, 2025 | 75 | -20.21% | 24,665,288 | -42.60% | 53 | 0.56% | 57 | -8.06% | 9 | -40.00% |
| Sep 30, 2025 | 49 | -33.78% | 17,110,255 | -55.94% | 39 | 0.50% | 34 | -19.05% | 7 | -46.15% |
| Jun 30, 2025 | 74 | 15.63% | 38,836,437 | 8.98% | 88 | 0.57% | 42 | -34.38% | 13 | - |
| Mar 31, 2025 | 67 | - | 40,037,113 | - | 139 | - | 67 | - | - | - |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 1.16M | 2.34% | - |
| Fidelity Select Biotechnology | 739.66K | 1.34% | 427.77K |
| iShares Russell 2000 ETF | 634.98K | 1.15% | 5.88K |
| Janus Henderson Hrzn Biotec E2 USD | 514.40K | 1.03% | - |
| JPMorgan Small Cap Growth A | 433.13K | 0.78% | 433.13K |
| Eventide Healthcare & Life Sciences I | 324.04K | 0.65% | 324.04K |
| T. Rowe Price Small-Cap Stock | 295.57K | 0.53% | 295.57K |
| Vanguard Institutional Extnd Mkt Idx Tr | 239.07K | 0.48% | 3.98K |
| Fidelity Small Cap Index | 259.43K | 0.47% | 49.52K |
| iShares Biotechnology ETF | 232.78K | 0.42% | 4.46K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Jul 01, 2026 | Bernstein Harold | President, R&D & CMO | Sell | $400.46K |
| Jul 01, 2026 | Bernstein Harold | President, R&D & CMO | Sell | $36.40K |
| Jul 01, 2026 | Coloma Jason V | Chief Executive Officer | Sell | $907.92K |
| Jul 01, 2026 | Coloma Jason V | Chief Executive Officer | Sell | $48.61K |
| Jul 01, 2026 | Coloma Jason V | Chief Executive Officer | Sell | $77.73K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q3 | - | 5 |
| 2026 Q2 | - | 21 |
| 2026 Q1 | - | 25 |
| 2025 Q4 | - | 8 |
| 2025 Q3 | - | 1 |
MAZE Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools